Skip to main content

Table 1 Demographics

From: Safety of 4-factor prothrombin complex concentrate (4F-PCC) for emergent reversal of factor Xa inhibitors

Demographics n (%)
Total patients 43
Median age (year) 74
Gender
 Male 23 (53.5)
 Female 20 (46.5)
Anticoagulation  
 Rivaroxaban 21 (48.8)
 Apixaban 22 (51.2)
 Edoxaban 0
Indication for anticoagulation
 Atrial fibrillation 30 (69.8)
 DVT/PE 9 (20.9)
 Atrial fibrillation and DVT/PE 3 (7.0)
 Lower extremity venous bypass graft 1 (2.3)
Indication for anticoagulation reversal
 Gastrointestinal bleeding 17 (39.5)
 Intracranial hemorrhage—non-traumatic 9 (20.9)
 Intracranial hemorrhage—traumatic 7 (16.3)
 Trauma 5 (14.0)
 Other 5 (11.6)
Invasive procedure after 4F-PCC administration 30 (69.8)
 Gastrointestinal endoscopies 16 (37.2)
 Interventional radiology embolization/coiling 3 (7.0)
 Craniotomy 3 (7.0)
 Orthopedic 3 (7.0)
 Other 5 (11.6)